Atlas Venture Associates IX, LLC - Q2 2019 holdings

$93.5 Million is the total value of Atlas Venture Associates IX, LLC's 7 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 0.0% .

 Value Shares↓ Weighting
NTLA  INTELLIA THERAPEUTICS INC$26,443,000
-4.2%
1,615,3210.0%28.28%
+9.1%
SYBX  SYNLOGIC INC$24,133,000
+19.9%
2,651,9630.0%25.81%
+36.5%
SPRO  SPERO THERAPEUTICS INC$15,849,000
-10.1%
1,376,9680.0%16.95%
+2.3%
SURF  SURFACE ONCOLOGY INC$13,100,000
-40.9%
4,645,4530.0%14.01%
-32.7%
UMRX  UNUM THERAPEUTICS INC$8,807,000
-40.3%
3,361,5350.0%9.42%
-32.1%
CBLK  CARBON BLACK INC$3,031,000
+19.8%
181,2730.0%3.24%
+36.4%
SNAP  SNAP INCcl a$2,147,000
+29.7%
150,1600.0%2.30%
+47.7%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-08-06
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
INTELLIA THERAPEUTICS INC28Q3 2023100.0%
SNAP INC26Q3 202311.4%
SPERO THERAPEUTICS INC24Q3 202324.0%
SYNLOGIC INC24Q2 202335.6%
SURFACE ONCOLOGY INC21Q2 202333.3%
SKILLZ INC12Q3 202387.5%
UNUM THERAPEUTICS INC11Q3 202028.2%
COGENT BIOSCIENCES INC7Q2 20229.6%
CARBON BLACK INC6Q3 20197.8%
COHERUS BIOSCIENCES INC1Q3 202318.1%

View Atlas Venture Associates IX, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2023-11-13
13F-HR2023-08-08
13F-HR2023-05-08
13F-HR2023-01-31
13F-HR2022-11-10
13F-HR2022-08-11
13F-HR2022-05-12
13F-HR2022-01-27
13F-HR2021-11-04
13F-HR2021-08-11

View Atlas Venture Associates IX, LLC's complete filings history.

Compare quarters

Export Atlas Venture Associates IX, LLC's holdings